clinical trial · NCT06500676
A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
KRAS G12D MutationsAdvanced Solid TumorsGFH375
brief summary
This is a multicenter, open-label, phase I/II study to explore the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of GFH375 in patients with advanced solid tumors harboring a KRAS G12D mutation.
started
Jul 9, 2024
primary completion
Jul 31, 2028
completion
Dec 31, 2028
last updated
Nov 20, 2025
official title
An Open-Label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of GFH375 in Patients With KRAS G12D Mutant Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol